S12 Ep50: Optimizing Today and Looking to Tomorrow in Metastatic CRPC - Homing in on EZH2

This Oncology PER®Spectives™ podcast explores the role of EZH2 in metastatic castration-resistant prostate cancer (mCRPC) progression and its synergy with androgen receptor inhibitors. In this podcast, experts Neeraj Agarwal, MD, FASCO; Himisha Beltran, MD; and Maha Hussain, MD, FACP, FASCO, discuss the management of mCRPC.Acknowledgment of Educational Grant SupportThis activity is supported by an educational grant from Pfizer Inc.Accreditation/Credit DesignationPhysicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.Instructions on How to Receive Credit Listen to this podcast in its entirety. Go to gotoper.com/credit and enter code: 6947 Answer the evaluation questions. Request credit using the drop-down menu. You may immediately download your certificate. Today’s faculty are:Neeraj Agarwal, MD, FASCOProfessor of MedicineSenior Director for Clinical ResearchHCI Presidential Endowed Chair of Cancer ResearchDirector, Center of Investigational TherapeuticsDirector, Genitourinary Oncology ProgramHuntsman Cancer Institute, University of Utah (NCI-CCC)Salt Lake City, UTDisclosures: Grant/Research Support (paid to institution): Arvinas, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, GlaxoSmithKline, Immunomedics, Janssen, Lava, Merck, Nektar, Neoleukin, Novartis, Oric, Pfizer, Roche, Sanofi, Seagen, Takeda, Tra-conHimisha Beltran, MDAssociate Professor of MedicineDirector of Translational Research Within Medical OncologyHarvard Medical SchoolLank Center for Genitourinary Oncology and the Division of Molecularand Cellular OncologyDana Farber Cancer InstituteBoston, MADisclosures: Grant/Research Support: Circle Pharma, Daiichi Sankyo, Novartis; Adviser: Amgen, AstraZeneca, Daiichi Sankyo, NovartisMaha Hussain, MD, FACP, FASCOGenevieve E. Teuton Professor of MedicineProfessor, Medicine (Hematology/Oncology)Deputy DirectorRobert H. Lurie Comprehensive Cancer CenterNorthwestern University Feinberg School of MedicineChicago, ILDisclosures: Advisory Board: AstraZeneca, Bayer, Convergent Therapeutics, Honoraria: AstraZeneca, BayerThe staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.Off-Label Disclosure and DisclaimerThis activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.Release DateMay 14, 2025Expiration DateMay 14, 2026